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aTo the Editor: Stent thrombosis (ST) is an infrequent but major
complication after percutaneous coronary intervention (PCI) and
frequently is associated with ST-segment elevation myocardial infarc-
tion (STEMI). As the population of stented patients has grown, the
number of patients at risk for STEMI resulting from ST has increased,
but data regarding the changing frequency and outcomes of STEMI
resulting from ST treated with primary PCI are limited (1–3).
Our study population consisted of 3,305 consecutive patients
with STEMI treated with emergency PCI at the Minneapolis
Heart Institute (n  2,086) or Cone Heart and Vascular Center
(n  1,219) from 2003 through 2010. Patients were treated with
contemporary standards for primary PCI. Patients at the Minne-
apolis Heart Institute transported from long distances were given
a half-dose of fibrinolytic therapy before transport.
Procedural data were entered by the interventional cardiologists.
Hospitalization and post-hospitalization data were obtained by
chart reviews and telephone contact by nurse coordinators. Defi-
nite ST was defined according to the Academic Research Consor-
tium definition. All major events were adjudicated by one of the
investigators (B.R.B., T.D.S., T.D.H.).
Categorical variables were compared using the chi-square or
Fisher exact test, and continuous variables were compared with the
Mann-Whitney U test. Kaplan-Meier estimates were compared
with log-rank statistics. Multivariate analyses were performed with
Cox regression.
Of 3,305 STEMI cases, 282 (8.5%) were the result of ST. The
frequency increased from 6.0% from 2003 through 2004 to 10.9%
from 2009 through 2010 (Fig. 1). The original stent implant was
a drug-eluting stent in 60% of patients, and 95% of these were
first-generation drug-eluting stents. The time from the original
stent implant to STEMI resulting from ST was early (0 to 30 days)
in 22%, late (31 to 365 days) in 22.0%, and very late (more than
365 days) in 56% of patients and was similar with a bare-metal
stent or drug-eluting stent. The original stent was implanted for
off-label indications in 73.6% of patients, including 43.3% for
STEMI. Compliance with dual antiplatelet therapy at the time of
ST was 33.5%, including 75.3% with early ST, 29.9% with late ST,
and 11.7% with very late ST.
Patients with STEMI resulting from ST versus de novo
occlusion had more diabetes, hypertension, prior myocardial in-
farction, and prior bypass surgery and had lower ejection fraction,
lower frequency of Thrombolysis In Myocardial Infarction flow
grade 2 to 3 on initial angiography, shorter door to balloon and
reperfusion times, and more frequent use of glycoprotein platelet
inhibitors and less frequent use of stents.
At 30 days, patients with STEMI resulting from ST had similar
mortality rates (6.4% vs. 5.1%, p  0.40) but more reinfarction
(6.0% vs. 1.8%, p  0.001) and ST (5.0% vs. 1.2%, p  0.001).linical follow-up was obtained at more than 1 year in 85.8% of
atients with a mean follow-up time of 2.1 years. At the 4-year
ollow-up, patients with STEMI resulting from ST had nonsig-
ificantly higher rates of cardiac mortality (16.8% vs. 11.3%, p 
.12) and higher rates of reinfarction (22.6% vs. 8.0%, p  0.001)
nd ST (15.2% vs. 4.1%, p  0.001) (Fig. 2).
After adjusting for differences in baseline variables, patients
with STEMI resulting from ST compared with those with de novo
occlusion had similar mortality (hazard ratio: 1.08, 95% confidence
interval: 0.74 to 1.58, p  0.68), but significantly higher rates of
reinfarction (hazard ratio: 2.59, 95% confidence interval: 1.85 to
3.63, p  0.001) and ST (hazard ratio: 3.43, 95% confidence
interval: 2.28 to 5.18, p  0.001).
Our study documents the increasing frequency of STEMI
resulting from ST and documents worse outcomes compared with
those associated with de novo coronary occlusion with higher
frequencies of reinfarction and ST. Our study shares similarities
with 3 smaller single-center studies, but with some key differences
(1–3). Two of the 3 smaller studies found worse procedural
outcomes and higher mortality in patients with STEMI resulting
from ST, whereas our study did not. All 3 studies found higher
rates of late reinfarction in patients with STEMI resulting from
ST, similar to our study.
The increasing relative frequency of STEMI resulting from ST
probably can be explained by the increasing number of patients
Figure 1
Frequency of STEMI Resulting From Stent
Thrombosis as a Percentage of all STEMI
Patients Treated With Primary Percutaneous
Coronary Intervention From 2003 Through 2010
The percentage of patients whose original stent implant was a bare-metal stent
(BMS) is shown in blue and whose original stent implant was a drug-eluting stent
(DES) is shown in red. STEMI  ST-segment elevation myocardial infarction.
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November 6, 2012:1989–92who are at risk for very late ST, the fact that patients with stents
seem to be at risk for ST for many years after implantation, and the
fact that there has been some decrease in the frequency of STEMI
resulting from de novo coronary occlusion. In our study, most patients
with STEMI resulting from ST had very late ST (1 year). It is also
ossible that the threshold for diagnosing ST could have changed over
he study period because of changing thresholds for performing
ngiography in patients with acute coronary syndromes.
Efforts at prevention of STEMI resulting from ST include opti-
izing initial stent deployment, the use of new-generation stents, and
he use of new and better antiplatelet therapy, including prasugrel and
icagrelor. These measures are most important when stents are
mplanted for off-label indications, especially for STEMI.
More aggressive management strategies in this high-risk group of
atients may be required to improve outcomes. Because procedural
esults have been shown to be poorer in some studies, new procedural
trategies may be needed, including increased use of glycoprotein
latelet inhibitors, the more frequent use of thrombectomy devices
nd intravascular ultrasound to guide therapy, and the use of new-
eneration stents when new stents are required. The use of new
ntiplatelet agents, such as prasugrel and ticagrelor, which have been
hown to reduce the frequency of ST in STEMI patients, should be
sed in eligible patients, and more frequent prophylactic revascular-
zation with bypass surgery may be warranted.
In conclusion, ST accounts for an increasing proportion of
TEMI patients and is associated with an increased frequency of
einfarction and subsequent ST compared with de novo coronary
rtery occlusion. New strategies are needed to address this growing
Figure 2 Kaplan-Meier Estimates of Cumulative Frequency of ReinfarctiIntervention Comparing Patients with STEMI Resulting From S
The number of subjects entering each interval for reinfarction is shown in red, with
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Does Pregnancy Influence the
bstitutes?To the Editor: There is insufficient published evidence about the
potential degenerative effects of pregnancy on the homograft and
pulmonary autograft in the aortic position. To assess the associa-
tion between pregnancy and accelerated degeneration of human
aortic valve substitutes, we conducted a retrospective analysis of a
prospective cohort study of female patients who received a human
tissue valve in the aortic position at our institution.
All patients who have received a homograft or autograft in the
aortic position in our center since 1987 are enrolled in an ongoing
prospective follow-up study (1). Patients undergo annual clinical
follow-up and biennial standardized serial echocardiography
(aortic gradient [Vmax]), aortic regurgitation (AoI), and annular
and sinotubular junction diameter (AD and STJ). We identified
108 female patients who underwent 59 homograft and 49 autograft
procedures, and who were50 years old at the time of surgery and
t least 16 years old at the time of study (age 29  13 years).
Informed consent was obtained from the patients to interview
them (December 2010) for additional information on pregnancy
and cardiac status (institutional review board number 2010–272).
Figure 1 Vmax, STJ Diameter, AD, and AoI Marginal Probability
(Top row) Homograft models. (Bottom row) Autograft models. (Shaded grey areaFreestanding root replacement with reimplantation of the coronary
arteries was performed in most patients. Fifteen homograft patients
underwent a subcoronary homograft implantation, and 2 autograft
patients had an inclusion cylinder aortic root replacement.
Outcome was reported according to the 2008 American Asso-
ciation of Thoracic Surgery/European Association of Cardio-
Thoracic Surgery/Society of Thoracic Surgeons guidelines for
reporting mortality and morbidity after cardiac valve interventions.
Mixed-effects models were used to assess changes in echocardio-
graphic measurements over time while accounting for within-
patient correlation between repeated follow-up measurements (2).
Total follow-up was 1,448 patient years and 99% complete.
Ninety-nine patients had 1 echocardiographic examinations
(median 6; range 1 to 11).
Thirty-one patients (13 homografts and 18 autografts) experi-
enced 55 pregnancies, including 48 completed pregnancies, 4
elective abortions for noncardiac reasons, and 3 miscarriages.
Homograft recipients without pregnancies were older than
homograft recipients who became pregnant (35 vs. 28 years;
I Grade Over Time
confidence intervals. AD  annulus diameter; AoI  aortic regurgitation;of Ao
s) 95%
STJ  sinotubular junction; V  peak velocity,
